X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-11-14 | CRMD | Cormedix Inc. | Dillione Janet | Dir | S - Sale | $11.42 | -30,000 | 48,473 | -38% | -$342,600 | ||||||
| DM | 2025-11-17 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $44.19 | -10,560 | 66,520 | -14% | -$466,631 | |||||
2025-11-17 | BBIO | Bridgebio Pharma, Inc. | Trimarchi Thomas | Pres, CFO | S - Sale | $66.46 | -16,934 | 382,830 | -4% | -$1,125,404 | ||||||
| D | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | GC, Secretary | S - Sale+OE | $8.91 | -4,319 | 62,626 | -6% | -$38,503 | |||||
| D | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | COO, CFO | S - Sale+OE | $8.91 | -4,062 | 294,715 | -1% | -$36,212 | |||||
| D | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Chief Commercial Officer | S - Sale+OE | $8.91 | -3,726 | 50,809 | -7% | -$33,216 | |||||
| D | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | CEO | S - Sale+OE | $8.91 | -15,894 | 1,786,003 | -1% | -$141,690 | |||||
2025-11-14 | NATR | Natures Sunshine Products Inc | Brower Nathan G | EVP, GC | S - Sale | $20.81 | -3,800 | 46,735 | -8% | -$79,078 | ||||||
2025-11-14 | RNTX | Rein Therapeutics, Inc. | Voss Capital, LP | 10% | P - Purchase | $1.22 | +104,183 | 1,426,441 | +8% | +$127,593 | ||||||
2025-11-18 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.27 | +533,300 | 248,662,576 | 0% | +$678,906 | ||||||
| D | 2025-11-17 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $470.43 | -22,500 | 2,648 | -89% | -$10,584,756 | |||||
2025-11-14 | TRDA | Entrada Therapeutics, Inc. | Parmar Kush | Dir, 10% | S - Sale | $8.80 | -200,000 | 4,056,379 | -5% | -$1,760,000 | ||||||
| D | 2025-11-17 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $470.36 | -21,000 | 8,118 | -72% | -$9,877,535 | |||||
| DM | 2025-11-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $465.25 | -8,000 | 644,489 | -1% | -$3,721,967 | |||||
2025-11-14 | TRDA | Entrada Therapeutics, Inc. | 5Am Ventures V, L.P. | 10% | S - Sale | $8.80 | -200,000 | 4,056,379 | -5% | -$1,760,000 | ||||||
| D | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | See Remarks | S - Sale+OE | $17.30 | -1,042 | 8,401 | -11% | -$18,027 | |||||
| D | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $17.30 | -217 | 11,113 | -2% | -$3,754 | |||||
| D | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $17.30 | -76 | 7,623 | -1% | -$1,315 | |||||
| D | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $17.30 | -1,257 | 7,527 | -14% | -$21,746 | |||||
2025-11-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $25.20 | -10,916 | 691,453 | -2% | -$275,047 | ||||||
2025-11-18 | RMTI | Rockwell Medical, Inc. | Cooper John G | Dir | S - Sale | $0.87 | -5,079 | 140,372 | -3% | -$4,419 | ||||||
2025-11-17 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $25.19 | -8,500 | 401,142 | -2% | -$214,091 | ||||||
| D | 2025-11-18 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $66.45 | -2,200 | 140,610 | -2% | -$146,190 | |||||
2025-11-14 | STOK | Stoke Therapeutics, Inc. | Krainer Adrian R. | Dir | S - Sale | $26.98 | -40,472 | 364,246 | -10% | -$1,092,058 | ||||||
2025-11-17 | INSM | Insmed Inc | Lee Leo | Dir | S - Sale | $195.90 | -75,000 | 54,677 | -58% | -$14,692,249 | ||||||
2025-11-14 | INSM | Insmed Inc | Anderson Elizabeth M | Dir | S - Sale | $195.87 | -10,000 | 63,729 | -14% | -$1,958,700 | ||||||
| D | 2025-11-17 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $27.64 | -6,000 | 105,386 | -5% | -$165,835 | |||||
| D | 2025-11-17 | CNTA | Centessa Pharmaceuticals Plc | Bush Tia L | Chief Technology, Quality Ofc | S - Sale+OE | $28.00 | -40,000 | 121,503 | -25% | -$1,120,000 | |||||
2025-11-18 | BIXT | Bioxytran, Inc | Hoberman Alan M | Dir | P - Purchase | $0.60 | +210,000 | 626,207 | +50% | +$126,000 | ||||||
2025-11-14 | TEVA | Teva Pharmaceutical Industries Ltd | Fox Christine | EVP, Head of U.S. Commercial | S - Sale | $25.11 | -30,000 | 28,384 | -51% | -$753,321 | ||||||
| E | 2025-11-17 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.21 | -9,886 | 92,872,191 | 0% | -$2,062 | |||||
2025-11-17 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $20.06 | -5,000 | 168,866 | -3% | -$100,300 | ||||||
2025-11-14 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $2.11 | +15,000 | 2,693,896 | +1% | +$31,650 | ||||||
2025-11-17 | BHVN | Biohaven Ltd. | Clark George C. | VP, Chief Accounting Officer | P - Purchase | $8.52 | +17,000 | 85,595 | +25% | +$144,770 | ||||||
2025-11-17 | TTRX | Turn Therapeutics Inc. | Chaudhary Zuraiz | See Remarks | P - Purchase | $3.62 | +2,500 | 7,550 | +50% | +$9,050 | ||||||
| D | 2025-11-13 | ARQT | Arcutis Biotherapeutics, Inc. | Krishnamohan Neha | Dir | S - Sale+OE | $23.20 | -40,504 | 22,123 | -65% | -$939,494 | |||||
| M | 2025-11-13 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.96 | -134,553 | 3,515,880 | -4% | -$128,785 | |||||
| M | 2025-11-13 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $0.96 | -209,652 | 5,481,539 | -4% | -$200,665 | |||||
| M | 2025-11-13 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $0.96 | -209,652 | 5,481,539 | -4% | -$200,665 | |||||
| M | 2025-11-13 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | COO | S - Sale | $16.04 | -131,411 | 296,570 | -31% | -$2,108,067 | |||||
2025-11-13 | ANIP | Ani Pharmaceuticals Inc | Walsh Patrick D | Dir | S - Sale | $86.88 | -8,643 | 58,405 | -13% | -$750,904 | ||||||
| D | 2025-11-13 | XERS | Xeris Biopharma Holdings, Inc. | Shannon John Patrick Jr | See Remarks | S - Sale+OE | $7.46 | -23,242 | 2,730,253 | -1% | -$173,402 | |||||
| M | 2025-11-13 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% | S - Sale | $20.46 | -1,854,603 | 47,011,613 | -4% | -$37,939,112 | |||||
2025-11-13 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $5.25 | +276,179 | 4,767,910 | +6% | +$1,449,940 | ||||||
2025-11-13 | MRVI | Maravai Lifesciences Holdings, Inc. | Brust Bernd | CEO | P - Purchase | $3.25 | +216,212 | 2,466,771 | +10% | +$702,689 | ||||||
| M | 2025-11-13 | FGEN | Fibrogen Inc | Wettig Thane | CEO | P - Purchase | $9.12 | +3,700 | 24,979 | +17% | +$33,750 | |||||
| D | 2025-11-13 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale+OE | $26.49 | -16,679 | 75,531 | -18% | -$441,837 | |||||
| DM | 2025-11-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Leiden Jeffrey M | Exec COB | S - Sale+OE | $440.60 | -73,292 | 24,466 | -75% | -$32,292,320 | |||||
| D | 2025-11-14 | AVTX | Avalo Therapeutics, Inc. | Goldman Jonathan | Dir | S - Sale+OE | $14.33 | -11,367 | 0 | -100% | -$162,937 | |||||
| E | 2025-11-14 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $11.59 | -178,295 | 92,882,077 | 0% | -$2,065,796 | |||||
| M | 2025-11-13 | CRVO | Cervomed Inc. | Gregoire Sylvie | Dir, 10% | P - Purchase | $7.53 | +7,847 | 1,474,978 | +1% | +$59,101 | |||||
| M | 2025-11-13 | CRVO | Cervomed Inc. | Alam John J | CEO, Pres, 10% | P - Purchase | $7.53 | +7,847 | 1,474,978 | +1% | +$59,101 | |||||
2025-11-14 | CRVO | Cervomed Inc. | Winton Matthew | Chief Commercial, Business | P - Purchase | $7.57 | +10,000 | 10,000 | New | +$75,700 | ||||||
2025-11-13 | CATX | Perspective Therapeutics, Inc. | Hunt Jonathan Robert | Chief Accounting Officer | P - Purchase | $2.03 | +11,000 | 59,800 | +23% | +$22,295 | ||||||
2025-11-13 | BHVN | Biohaven Ltd. | Bailey Gregory | Dir | P - Purchase | $7.50 | +400,000 | 2,020,071 | +25% | +$3,000,000 | ||||||
2025-11-13 | BHVN | Biohaven Ltd. | Childs John W | Dir | P - Purchase | $7.50 | +3,333,333 | 9,876,729 | +51% | +$24,999,998 | ||||||
2025-11-13 | BHVN | Biohaven Ltd. | Coric Vlad | CEO | P - Purchase | $7.50 | +666,666 | 3,842,534 | +21% | +$4,999,995 | ||||||
| DM | 2025-11-13 | DNTH | Dianthus Therapeutics, Inc. /De/ | Randhawa Simrat | EVP, Head of R, D | S - Sale+OE | $37.55 | -196,538 | 4,000 | -98% | -$7,379,887 | |||||
2025-11-13 | WVE | Wave Life Sciences Ltd. | Rawcliffe Adrian | Dir | S - Sale | $6.79 | -16,115 | 12,700 | -56% | -$109,421 | ||||||
| D | 2025-11-14 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Officer | S - Sale+OE | $30.00 | -3,333 | 84,974 | -4% | -$99,990 | |||||
2025-11-14 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $11.18 | -8,804 | 188,139 | -4% | -$98,401 | ||||||
2025-11-14 | MNKD | Mannkind Corp | Singh Sanjay R | EVP Technical Operations | S - Sale | $5.03 | -18,777 | 455,211 | -4% | -$94,448 | ||||||
2025-11-14 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $11.18 | -8,887 | 139,689 | -6% | -$99,329 | ||||||
2025-11-14 | KURA | Kura Oncology, Inc. | Leoni Mollie | Chief Medical Officer | S - Sale | $11.18 | -15,485 | 225,454 | -6% | -$173,074 | ||||||
2025-11-14 | KURA | Kura Oncology, Inc. | Doyle Thomas James | SVP, Finance, Accounting | S - Sale | $11.18 | -4,539 | 130,757 | -3% | -$50,732 | ||||||
2025-11-14 | KURA | Kura Oncology, Inc. | Ford Kathleen | COO | S - Sale | $11.18 | -6,902 | 105,373 | -6% | -$77,143 | ||||||
| D | 2025-11-13 | SPRY | Ars Pharmaceuticals, Inc. | Dorsey Brian | COO | S - Sale+OE | $8.71 | -21,828 | 10,789 | -67% | -$190,050 | |||||
| D | 2025-11-12 | SPRY | Ars Pharmaceuticals, Inc. | Chakma Justin | Chief Business Officer | S - Sale+OE | $8.87 | -166,380 | 0 | -100% | -$1,476,147 | |||||
2025-11-13 | WVE | Wave Life Sciences Ltd. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $6.69 | +1,000 | 18,231,824 | 0% | +$6,688 | ||||||
| M | 2025-11-12 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $365.22 | -16,009 | 1,037,226 | -2% | -$5,846,820 | |||||
| D | 2025-11-12 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $349.17 | -996 | 223,106 | 0% | -$347,770 | |||||
| D | 2025-11-12 | PTCT | Ptc Therapeutics, Inc. | Reeve Emma | Dir | S - Sale+OE | $74.50 | -7,333 | 6,666 | -52% | -$546,309 | |||||
| D | 2025-11-12 | AMRX | Amneal Pharmaceuticals, Inc. | Shah Nikita | EVP | S - Sale+OE | $11.92 | -131,856 | 146,403 | -47% | -$1,571,724 | |||||
| D | 2025-11-13 | MDGL | Madrigal Pharmaceuticals, Inc. | Levy Richard S | Dir | S - Sale+OE | $520.96 | -8,500 | 21,197 | -29% | -$4,428,198 | |||||
2025-11-12 | CPRX | Catalyst Pharmaceuticals, Inc. | Elsbernd Brian | Chief Compliance, Legal Office | S - Sale | $22.70 | -40,000 | 231,039 | -15% | -$908,000 | ||||||
| D | 2025-11-12 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | S - Sale+OE | $66.07 | -25,484 | 7,863 | -76% | -$1,683,728 | |||||
| D | 2025-11-12 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $40.94 | -19,900 | 31,086 | -39% | -$814,706 | |||||
| M | 2025-11-12 | ANIP | Ani Pharmaceuticals Inc | Gassert Chad | SVP - CORP. DEV., STRATEGY | S - Sale | $89.06 | -14,736 | 232,105 | -6% | -$1,312,435 | |||||
2025-11-13 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $4.74 | -15,000 | 62,252 | -19% | -$71,168 | ||||||
2025-11-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $87.27 | -400 | 75,274 | -1% | -$34,908 | ||||||
| DM | 2025-11-12 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale+OE | $452.75 | -25,650 | 65,816 | -28% | -$11,613,003 | |||||
| D | 2025-11-12 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale+OE | $194.00 | -30,000 | 36,461 | -45% | -$5,820,061 | |||||
| D | 2025-11-12 | COLL | Collegium Pharmaceutical, Inc | Fallon John A. | Dir | S - Sale+OE | $47.21 | -34,853 | 64,634 | -35% | -$1,645,536 | |||||
| D | 2025-11-12 | AGIO | Agios Pharmaceuticals, Inc. | Scadden David | Dir | S - Sale+OE | $43.84 | -200 | 17,603 | -1% | -$8,768 | |||||
| D | 2025-11-13 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $5.47 | -121,117 | 4,479 | -96% | -$662,510 | |||||
| E | 2025-11-13 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.04 | -46,606 | 93,060,372 | 0% | -$2,062 | |||||
2025-11-12 | CVRX | Cvrx, Inc. | Johnson & Johnson | 10% | S - Sale | $10.00 | -1,000 | 4,049,898 | 0% | -$10,000 | ||||||
2025-11-12 | PRGO | Perrigo Co Plc | Parker Geoffrey M. | Dir | P - Purchase | $14.18 | +7,500 | 72,166 | +12% | +$106,350 | ||||||
2025-11-13 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | SVP, Sales | P - Purchase | $0.10 | +150,000 | 5,784,101 | +3% | +$14,550 | ||||||
2025-11-12 | CATX | Perspective Therapeutics, Inc. | Williamson Robert F III | Dir | P - Purchase | $2.10 | +9,498 | 118,846 | +9% | +$19,946 | ||||||
| AD | 2025-11-11 | TBPH | Theravance Biopharma, Inc. | Broshy Eran | Dir | S - Sale+OE | $17.98 | -45,000 | 60,204 | -43% | -$809,250 | |||||
| D | 2025-11-11 | TBPH | Theravance Biopharma, Inc. | Broshy Eran | Dir | S - Sale+OE | $18.11 | -59,000 | 46,204 | -56% | -$1,068,250 | |||||
| D | 2025-11-11 | VERA | Vera Therapeutics, Inc. | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | S - Sale+OE | $29.06 | -15,000 | 57,839 | -21% | -$435,875 | |||||
| DM | 2025-11-12 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $45.01 | -30,337 | 22,080 | -58% | -$1,365,393 | |||||
| D | 2025-11-11 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $84.70 | -30,000 | 40,555 | -43% | -$2,540,923 | |||||
2025-11-10 | SEPN | Septerna, Inc. | Long Daniel D. | SVP, Drug Discovery | S - Sale | $18.06 | -3,501 | 92,911 | -4% | -$63,223 | ||||||
| D | 2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale+OE | $44.88 | -119,524 | 19,396 | -86% | -$5,363,716 | |||||
2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $45.44 | -200,000 | 631,305 | -24% | -$9,088,499 | ||||||
| D | 2025-11-13 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | S - Sale+OE | $45.99 | -15,000 | 0 | -100% | -$689,797 | |||||
| DM | 2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Gold Alexander M | Dir | S - Sale+OE | $45.45 | -34,675 | 0 | -100% | -$1,576,095 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |